In the precision-driven world of pharmaceutical manufacturing, every chemical intermediate plays a crucial role. For the synthesis of Lacosamide, a widely used antiepileptic drug, (R)-N-Benzyl-2-(benzyloxycarbonylamino)-3-hydroxypropionamide (CAS 219835-31-1) is a cornerstone intermediate. Understanding its precise specifications is not just about quality assurance; it's fundamental to the safety, efficacy, and regulatory compliance of the final drug product.

This article aims to demystify the key specifications that procurement managers and R&D scientists should look for when sourcing this critical compound from any manufacturer or supplier, particularly from leading regions like China. These parameters are designed to guarantee the compound's suitability for pharmaceutical applications and ensure a consistent, reproducible synthesis process.

Key Specifications for (R)-N-Benzyl-2-(benzyloxycarbonylamino)-3-hydroxypropionamide:

• Appearance: The standard description is 'White to off-white powder.' Any significant deviation from this can indicate potential contamination or degradation.
• Purity: While not explicitly stated as a percentage in all sources, typical pharmaceutical intermediates require high purity, often exceeding 98%. This is critical for minimizing side reactions and ensuring the final API meets stringent pharmacopeial standards.
• Loss on Drying (LOD): This specification, usually stated as '≤1.0%,' measures the amount of volatile matter, primarily moisture, in the sample. Low LOD is essential for stability and accurate weighing during synthesis.
• Specific Rotation: As a chiral compound, its specific rotation is a critical indicator of its enantiomeric purity. Values like '+4.4º~+5.1º (C=1g/100ml in MeOH)' are precise and confirm the correct stereochemistry is present. Deviation here can lead to the formation of inactive or even harmful isomers.
• Melting Point: A defined melting point range, such as '147-152°C' (or 147-149°C as per initial data), serves as a key physical characteristic and an indicator of purity. A broad or depressed melting range typically suggests impurities.
• Residue on Ignition (ROI): This test quantifies inorganic impurities. A value of '≤0.1%' indicates that the inorganic content is well below acceptable limits for pharmaceutical intermediates.
• Heavy Metals: '≤20ppm' is a standard pharmaceutical limit for heavy metal contamination, ensuring the product is safe for use in drug manufacturing.

When you decide to buy (R)-N-Benzyl-2-(benzyloxycarbonylamino)-3-hydroxypropionamide, especially from an overseas Lacosamide intermediate manufacturer, always request a detailed Certificate of Analysis (CoA) that confirms these specifications. Comparing CoAs from different suppliers can help you identify the most reliable sources. For those seeking to purchase this pharmaceutical intermediate, verifying these details with potential suppliers is a non-negotiable step in the procurement process.

By thoroughly understanding and demanding these specifications, pharmaceutical professionals can ensure they are sourcing high-quality intermediates that meet the rigorous demands of drug synthesis, ultimately contributing to safer and more effective treatments for patients.